{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:09:43Z","timestamp":1784945383428,"version":"3.55.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["MH063266"],"award-info":[{"award-number":["MH063266"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>New treatments for stress-related disorders including depression, anxiety, and substance use disorder are greatly needed. Kappa opioid receptors are expressed in the central nervous system, including areas implicated in analgesia and affective state. Although kappa opioid receptor agonists share the antinociceptive effects of mu opioid receptor agonists, they also tend to produce negative affective states. In contrast, selective kappa opioid receptor antagonists have antidepressant- and anxiolytic-like effects, stimulating interest in their therapeutic potential. The prototypical kappa opioid receptor antagonists (e.g., norBNI, JDTic) have an exceptionally long duration of action that complicates their use in humans, particularly in tests to establish safety. This study was designed to test dose- and time-course effects of novel kappa opioid receptor antagonists with the goal of identifying short-acting lead compounds for future medication development.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We screened 2 novel, highly selective kappa opioid receptor antagonists (CYM-52220 and CYM-52288) with oral efficacy in the warm water tail flick assay in rats to determine initial dose and time course effects. For comparison, we tested existing kappa opioid receptor antagonists JDTic and LY-2456302 (also known as CERC-501 or JNJ-67953964).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the tail flick assay, the rank order of duration of action for the antagonists was LY-2456302\u2009&lt;\u2009CYM-52288\u2009&lt;\u2009CYM-52220 &lt;&lt; JDTic. Furthermore, LY-2456302 blocked the depressive (anhedonia-producing) effects of the kappa opioid receptor agonist U50,488 in the intracranial self-stimulation paradigm, albeit at a higher dose than that needed for analgesic blockade in the tail flick assay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These results suggest that structurally diverse kappa opioid receptor antagonists can have short-acting effects and that LY-2456302 reduces anhedonia as measured in the intracranial self-stimulation test.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ijnp\/pyz054","type":"journal-article","created":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T19:51:20Z","timestamp":1570737080000},"source":"Crossref","is-referenced-by-count":8,"title":["Behavioral Pharmacology of Novel Kappa Opioid Receptor Antagonists in Rats"],"prefix":"10.1093","author":[{"given":"Sarah","family":"Page","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria M","family":"Mavrikaki","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Lintz","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Puttick","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Rosen","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F Ivy","family":"Carroll","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A","family":"Carlezon","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena H","family":"Chartoff","sequence":"additional","affiliation":[{"name":"Research Triangle Institute, Research Triangle Park, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"2019110603360433700_CIT0001","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s00213-001-0949-2","article-title":"Sex and rat strain determine sensitivity to kappa opioid-induced antinociception","volume":"160","author":"Barrett","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"2019110603360433700_CIT0002","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00213-005-0167-4","article-title":"Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats","volume":"183","author":"Beardsley","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"2019110603360433700_CIT0003","article-title":"Blackthorn therapeutics initiates phase 1 study of BTRX-335140, an Investigational Kappa Opioid Receptor (KOR) antagonist.","author":"BlackThorn","year":"2018"},{"key":"2019110603360433700_CIT0004","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pharmthera.2019.04.009","article-title":"Targeting opioid dysregulation in depression for the development of novel therapeutics","volume":"201","author":"Browne","year":"2019","journal-title":"Pharmacol Ther"},{"key":"2019110603360433700_CIT0005","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00213-010-1806-y","article-title":"Kinase cascades and ligand-directed signaling at the kappa opioid receptor","volume":"210","author":"Bruchas","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"2019110603360433700_CIT0006","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.brainres.2009.08.062","article-title":"The dynorphin\/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors","volume":"1314","author":"Bruchas","year":"2010","journal-title":"Brain Res"},{"key":"2019110603360433700_CIT0007","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejphar.2007.05.007","article-title":"Reinstatement of cocaine place-conditioning prevented by the peptide kappa-opioid receptor antagonist arodyn","volume":"569","author":"Carey","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"2019110603360433700_CIT0008","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1038\/nprot.2007.441","article-title":"Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation","volume":"2","author":"Carlezon","year":"2007","journal-title":"Nat Protoc"},{"key":"2019110603360433700_CIT0009","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/da.22500","article-title":"Kappa-opioid antagonists for psychiatric disorders: from bench to clinical trials","volume":"33","author":"Carlezon","year":"2016","journal-title":"Depress Anxiety"},{"key":"2019110603360433700_CIT0010","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1021\/jm301783x","article-title":"Development of \u03ba opioid receptor antagonists","volume":"56","author":"Carroll","year":"2013","journal-title":"J Med Chem"},{"key":"2019110603360433700_CIT0011","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejphar.2004.08.028","article-title":"Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist","volume":"501","author":"Carroll","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"2019110603360433700_CIT0012","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.neuropharm.2011.06.014","article-title":"Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats","volume":"62","author":"Chartoff","year":"2012","journal-title":"Neuropharmacology"},{"key":"2019110603360433700_CIT0013","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/FBP.0000000000000080","article-title":"Drug withdrawal conceptualized as a stressor","volume":"25","author":"Chartoff","year":"2014","journal-title":"Behav Pharmacol"},{"key":"2019110603360433700_CIT0014","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/npp.2015.74","article-title":"Kappa antagonist JDTic in phase 1 clinical trial","volume":"40","author":"Chavkin","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"2019110603360433700_CIT0015","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/FBP.0000000000000155","article-title":"Effects of acute and chronic social defeat stress are differentially mediated by the dynorphin\/kappa-opioid receptor system","volume":"26","author":"Donahue","year":"2015","journal-title":"Behav Pharmacol"},{"key":"2019110603360433700_CIT0016","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00213-010-1836-5","article-title":"Depressive-like effects of the kappa opioid receptor agonist salvinorin A are associated with decreased phasic dopamine release in the nucleus accumbens","volume":"210","author":"Ebner","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"2019110603360433700_CIT0017","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/npp.2014.330","article-title":"Evaluation of opioid modulation in major depressive disorder","volume":"40","author":"Ehrich","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"2019110603360433700_CIT0018","first-page":"30","article-title":"Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo","volume":"316","author":"Endoh","year":"1992","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"2019110603360433700_CIT0019","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1176\/appi.ajp.2015.15070921","article-title":"Opioid modulation with buprenorphine\/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial","volume":"173","author":"Fava","year":"2016","journal-title":"Am J Psychiatry"},{"key":"2019110603360433700_CIT0020","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1021\/acs.jmedchem.8b01679","article-title":"Design and synthesis of a novel and selective kappa opioid receptor (KOR) antagonist (BTRX-335140)","volume":"62","author":"Guerrero","year":"2019","journal-title":"J Med Chem"},{"key":"2019110603360433700_CIT0021","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/0024-3205(82)90209-0","article-title":"Dynorphin: potent analgesic effect in spinal cord of the rat","volume":"31","author":"Han","year":"1982","journal-title":"Life Sci"},{"key":"2019110603360433700_CIT0022","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.brainres.2009.09.074","article-title":"Dynorphin, stress, and depression","volume":"1314","author":"Knoll","year":"2010","journal-title":"Brain Res"},{"key":"2019110603360433700_CIT0023","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1124\/jpet.107.127415","article-title":"Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats","volume":"323","author":"Knoll","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"2019110603360433700_CIT0024","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/nrd.2018.222","article-title":"The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development","volume":"18","author":"Krystal","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"2019110603360433700_CIT0025","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/npp.2017.120","article-title":"Role of \u03ba-opioid receptors in the bed nucleus of stria terminalis in reinstatement of alcohol seeking","volume":"43","author":"L\u00ea","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"2019110603360433700_CIT0026","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/jcph.286","article-title":"Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects","volume":"54","author":"Lowe","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"2019110603360433700_CIT0027","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00213-012-2912-9","article-title":"Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects","volume":"226","author":"MacLean","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"2019110603360433700_CIT0028","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/jpet.102.046433","article-title":"Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats","volume":"305","author":"Mague","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"2019110603360433700_CIT0029","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1006\/mcne.1994.1015","article-title":"Kappa 1 receptor mRNA distribution in the rat CNS: comparison to kappa receptor binding and prodynorphin mRNA","volume":"5","author":"Mansour","year":"1994","journal-title":"Mol Cell Neurosci"},{"key":"2019110603360433700_CIT0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0166-2236(95)93946-U","article-title":"Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications","volume":"18","author":"Mansour","year":"1995","journal-title":"Trends Neurosci"},{"key":"2019110603360433700_CIT0031","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1124\/mol.111.074195","article-title":"Duration of action of a broad range of selective \u03ba-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation","volume":"80","author":"Melief","year":"2011","journal-title":"Mol Pharmacol"},{"key":"2019110603360433700_CIT0032","doi-asserted-by":"crossref","first-page":"8000","DOI":"10.1021\/jm200789r","article-title":"Discovery of aminobenzyloxyarylamides as \u03ba opioid receptor selective antagonists: application to preclinical development of a \u03ba opioid receptor antagonist receptor occupancy tracer","volume":"54","author":"Mitch","year":"2011","journal-title":"J Med Chem"},{"key":"2019110603360433700_CIT0033","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2210-12-5","article-title":"Long-acting \u03ba opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity","volume":"12","author":"Munro","year":"2012","journal-title":"BMC Pharmacol"},{"key":"2019110603360433700_CIT0034","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s00213-004-1878-7","article-title":"Effects of the kappa opioid agonist U50,488 and the kappa opioid antagonist nor-binaltorphimine on choice between cocaine and food in rhesus monkeys","volume":"176","author":"Negus","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"2019110603360433700_CIT0035","doi-asserted-by":"crossref","first-page":"10883","DOI":"10.1523\/JNEUROSCI.22-24-10883.2002","article-title":"Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect","volume":"22","author":"Newton","year":"2002","journal-title":"J Neurosci"},{"key":"2019110603360433700_CIT0036","doi-asserted-by":"crossref","first-page":"9937","DOI":"10.1523\/JNEUROSCI.0953-16.2016","article-title":"Stress-induced reinstatement of nicotine preference requires dynorphin\/kappa opioid activity in the basolateral amygdala","volume":"36","author":"Nygard","year":"2016","journal-title":"J Neurosci"},{"key":"2019110603360433700_CIT0037","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1126\/science.3016896","article-title":"Psychotomimesis mediated by kappa opiate receptors","volume":"233","author":"Pfeiffer","year":"1986","journal-title":"Science"},{"key":"2019110603360433700_CIT0038","doi-asserted-by":"crossref","first-page":"7397","DOI":"10.1523\/JNEUROSCI.21-18-07397.2001","article-title":"Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens","volume":"21","author":"Pliakas","year":"2001","journal-title":"J Neurosci"},{"key":"2019110603360433700_CIT0039","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.biopsych.2011.05.021","article-title":"Repeated exposure to the \u03ba-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity","volume":"70","author":"Potter","year":"2011","journal-title":"Biol Psychiatry"},{"key":"2019110603360433700_CIT0040","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/npp.2017.245","article-title":"Repeated administration of opra kappa (LY2456302), a novel, short-acting, selective KOP-r antagonist, in persons with and without cocaine dependence","volume":"43","author":"Reed","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"2019110603360433700_CIT0041","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neuropharm.2013.09.021","article-title":"LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders","volume":"77","author":"Rorick-Kehn","year":"2014","journal-title":"Neuropharmacology"},{"key":"2019110603360433700_CIT0042","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.biopsych.2013.07.042","article-title":"Sex differences in sensitivity to the depressive-like effects of the kappa opioid receptor agonist U-50488 in rats","volume":"76","author":"Russell","year":"2014","journal-title":"Biol Psychiatry"},{"key":"2019110603360433700_CIT0043","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1523\/JNEUROSCI.2875-12.2016","article-title":"Nucleus accumbens AMPA receptors are necessary for morphine-withdrawal-induced negative-affective states in rats","volume":"36","author":"Russell","year":"2016","journal-title":"J Neurosci"},{"key":"2019110603360433700_CIT0044","doi-asserted-by":"crossref","first-page":"17582","DOI":"10.1523\/JNEUROSCI.3220-12.2012","article-title":"Stress produces aversion and potentiates cocaine reward by releasing endogenous dynorphins in the ventral striatum to locally stimulate serotonin reuptake","volume":"32","author":"Schindler","year":"2012","journal-title":"J Neurosci"},{"key":"2019110603360433700_CIT0045","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1523\/JNEUROSCI.19-05-01804.1999","article-title":"Cellular sites for dynorphin activation of kappa-opioid receptors in the rat nucleus accumbens shell","volume":"19","author":"Svingos","year":"1999","journal-title":"J Neurosci"},{"key":"2019110603360433700_CIT0046","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00213-003-1680-y","article-title":"Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats","volume":"172","author":"Todtenkopf","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"2019110603360433700_CIT0047","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.bmcl.2014.03.040","article-title":"Antagonists of the kappa opioid receptor","volume":"24","author":"Urbano","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"2019110603360433700_CIT0048","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1038\/npp.2013.58","article-title":"Ablation of kappa-opioid receptors from brain dopamine neurons has anxiolytic-like effects and enhances cocaine-induced plasticity","volume":"38","author":"Van\u2019t Veer","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"2019110603360433700_CIT0049","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/sj.npp.1301438","article-title":"Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence","volume":"33","author":"Walker","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"2019110603360433700_CIT0050","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.bmcl.2009.02.078","article-title":"Syntheses of novel high affinity ligands for opioid receptors","volume":"19","author":"Wentland","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"2019110603360433700_CIT0051","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1177\/0333102417702120","article-title":"Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention","volume":"37","author":"Xie","year":"2017","journal-title":"Cephalalgia"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyz054\/30437463\/pyz054.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyz054\/30437463\/pyz054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T13:33:55Z","timestamp":1611495235000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article\/doi\/10.1093\/ijnp\/pyz054\/5587707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":51,"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyz054","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,15]]},"article-number":"pyz054"}}